CareDx to Present 60 Abstracts, 19 Oral, at 2025 ISHLT Meeting
CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, has announced it will present 60 abstracts—including 19 oral presentations—at the 45th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), taking place April 27–30 in Boston, Massachusetts. The presentations, developed in collaboration with top transplant centers, highlight the latest clinical evidence supporting CareDx’s portfolio of transplant care solutions.
The company will showcase real-world applications and scientific advances across its core technologies, including HeartCare™, AlloSure® Heart, AlloMap® Heart, AlloSure® Lung, and the AlloHome™ remote monitoring platform. The findings span data from 92 transplant centers, underscoring the broad clinical adoption and continued momentum of CareDx’s molecular testing and digital health tools.
Advancing Clinical Utility in Transplant Care
“As real-world adoption of our heart and lung transplant solutions grows, so does the body of clinical evidence supporting their role in improving transplant outcomes,” said John W. Hanna, President and CEO of CareDx. “The latest results from our SHORE study show that HeartCare offers long-term prognostic insights beyond traditional biopsy data and supports real-world immunosuppression management.”
He added, “We’re proud to collaborate with leading transplant centers to deliver innovations that make a measurable difference for patients. This year’s ISHLT will feature two CareDx-sponsored symposia led by experts from institutions such as NY Presbyterian/Columbia, Penn Medicine, UCLA, UC San Diego, and the Miami Transplant Institute.”
Highlights from Heart Transplant Research
Several key findings will be presented on the clinical impact of HeartCare, a multimodal testing approach that integrates AlloSure Heart (donor-derived cell-free DNA) and AlloMap Heart (gene expression profiling):
- Prognostic Value: Dual-positive HeartCare results were found to predict worse outcomes, even when biopsy findings were normal (Abstract 240).
- Biopsy Reduction: Early surveillance using HeartCare showed equivalent 5-year survival and rejection-free rates compared to AlloMap and biopsy, with significantly fewer biopsies needed (Abstract 1351).
- Limited Biopsy Utility: Performing biopsies after dual-negative HeartCare results was not associated with better outcomes (Abstract 238).
- Immunosuppression Management: Physicians are using HeartCare results to tailor immunosuppression strategies, including lowering prednisone doses in low-risk patients (Abstract 187).
- Patient Subgroup Monitoring: HeartCare demonstrated reliability in detecting rejection across key subpopulations, including women (Abstract 61), Black Americans (Abstract 64), and those with chronic kidney disease (Abstract 1337).
Breakthroughs in Lung Transplant Monitoring
CareDx will also present data on AlloSure Lung and AlloHome, further demonstrating their value in post-transplant monitoring:
- Rejection Detection: AlloSure Lung effectively tracked donor-derived cell-free DNA (dd-cfDNA) levels, identifying the onset of acute cellular rejection and showing declines in dd-cfDNA after successful treatment (Abstract 1627).
- Remote Monitoring: The AlloHome platform enabled real-time adjustments in care and improved patient triage, easing clinical workloads and supporting better outcomes in lung transplant patients (Abstract 1204).
CareDx-Sponsored Symposia at ISHLT 2025
Two educational symposia hosted by CareDx will bring together experts to discuss the latest evidence and clinical applications for HeartCare and AlloSure Lung:
- HeartCare in 2025: Is Molecular Multimodality the Secret to Liquid Biopsy?
Moderated by Dr. Jeremy Kobulnik, CareDx Senior Medical Director, with panelists including:- Dr. Ersilia M. DeFilippis (NY Presbyterian/Columbia)
- Dr. H. Luise Holzhauser (Penn Medicine)
- Dr. Marcus Anthony Urey (UC San Diego Health)
- Dr. Benjamin Mackie (Tampa General Hospital)
- From Bench to Bedside: Is Lung Transplant Ready for the dd-cfDNA Revolution?
Moderated by Dr. Jake G. Natalini (NYU Langone), featuring panelists:- Dr. Ciara Shaver (Vanderbilt University)
- Dr. S. Samuel Weigt (UCLA)
- Dr. Juan Fernandez Castillo (Miami Transplant Institute)
About the SHORE Study
SHORE (Surveillance HeartCare Outcomes Registry) is one of the largest prospective heart transplant studies in the U.S., involving over 2,700 patients across 67 centers. It evaluates the effectiveness of HeartCare’s combined molecular approach in assessing allograft health and immune activity. Recent findings published in the Journal of Heart and Lung Transplantation confirmed that HeartCare outperforms dd-cfDNA alone in identifying rejection while reducing reliance on invasive biopsies.
About CareDx – The Transplant Company™
Headquartered in Brisbane, California, CareDx, Inc. is a precision medicine company dedicated to improving the lives of transplant patients and their caregivers. Through its advanced genomic testing, digital health solutions, and patient-centered services, CareDx supports the transplant journey from pre- to post-transplant. The company is widely recognized as a leader in providing clinically differentiated tools that drive better outcomes across the transplant community.
